ETF Daily News3d
Leerink Partnrs Analysts Lower Earnings Estimates for IDXX
Leerink Partnrs also issued estimates for IDEXX Laboratories’ Q2 2025 earnings at $3.22 EPS, Q3 2025 earnings at $3.04 EPS, Q4 2025 earnings at $2.84 EPS, FY2025 earnings at $11.86 EPS, FY2026 ...
ETF Daily News3d
Leerink Partnrs Analysts Lower Earnings Estimates for Genfit
Leerink Partnrs analyst T. Smith now expects that the company will earn $0.60 per share for the year, down from their previous estimate of $0.61. The consensus estimate for Genfit’s current full ...
Nasdaq6d
Leerink Partners Upgrades Regeneron Pharmaceuticals (LSE:0R2M)
Fintel reports that on February 5, 2025, Leerink Partners upgraded their outlook for Regeneron Pharmaceuticals (LSE:0R2M) from Market Perform to Outperform. There are 2,471 funds or institutions ...
Business Insider3d
Doximity upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Doximity (DOCS) to Outperform from Market Perform with a price target of $90, up from $60. While “admittedly late on this,” the firm sees the continuation of core growth ...
Business Insider5d
Regeneron upgraded to Outperform from Market Perform at Leerink
Leerink upgraded Regeneron (REGN) to Outperform from Market Perform with a price target of $834, up from $762. The shares have fallen 35% over the past six months, creating an opportunity to ...